THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to ...

Amgen on Friday revealed its PCSK9 drug Repatha (evolocumab) reduced the risk of major adverse cardiovascular events but had no effect on cardiovascular death, mixed results which could spell ...

The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL)cholesterol under control with current ...

Amgen Inc. raises 2025 revenue guidance on strong Repatha and Imdelltra sales and dividend hike. Click for this AMGN update.

Repatha (evolocumab) is a prescription drug used in certain situations to lower cholesterol and reduce serious heart-related risks. Repatha does this by attaching itself to a protein in your body ...

Pharmaceutical maker Amgen will lower the sticker price of its cholesterol drug Repatha (generic: evolocumab) by 60% to $5,850 a year, it announced Wednesday. Repatha is a PCSK9 inhibitor shown to ...

On the heels of highly anticipated cardiovascular outcomes data for PCSK9 med Repatha, Amgen has signed a money-back guarantee with Harvard Pilgrim. Through the first-of-its-kind contract, if a ...

Amgen has a new tool to employ in its battle with Sanofi and Regeneron for PCSK9 market dominance. The drugmaker said today that the FDA has approved a new hands-free injector for a once-monthly dose ...

Q. I developed severe depression while taking Repatha, the injectable cholesterol lowering drug. It took me a horrible nine months to realize the drug was making me suicidal. If I wasn’t sleeping, I ...

Amgen's cholesterol drug Repatha has a new use in Europe, as the company continues in its battle with Sanofi/Regeneron's rival therapy, Praluent. A PCSK9 inhibitor class drug, Repatha (evolocumab) is ...

A. Your doctor was correct that depression and suicidal thoughts do not appear in the official prescribing information for evolocumab (Repatha) or a similar drug, alirocumab (Praluent). Both are ...

For all the talk about new opportunities for consumers to make their own healthcare decisions, much remains out of their control. Nowhere is that more evident than in the prescription drug market, ...